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Abstract Wepresentatheoryaccordingwhichaheadache
treatment acts through a speciﬁc biological effect (when it
exists), a placebo effect linked to both expectancy and
repetition of its administration (conditioning), and a non-
speciﬁc psychological effect. The respective part of these
components varies with the treatments and the clinical
situations. During antiquity, suggestions and beliefs were
the mainstays of headache treatment. The word placebo
appeared at the beginning of the eighteenth century.
Controversies about its effect came from an excessive
interpretation due to methodological bias, inadequate
consideration of the variation of the measure (regression to
the mean) and of the natural course of the disease. Several
powerful studies on placebo effect showed that the nature
of the treatment, the associated announce, the patients’
expectancy, and the repetition of the procedures are of
paramount importance. The placebo expectancy is associ-
ated with an activation of pre-frontal, anterior cingular,
accumbens, and periacqueducal grey opioidergic neurons
possibly triggered by the dopaminergic meso-limbic sys-
tem. In randomized control trials, several arms design
could theoretically give information concerning the
respective part of the different component of the outcome
and control the natural course of the disease. However, for
migraine and tension type headache attacks treatment, no
three arm (verum, placebo, and natural course) trial is
available in the literature. Indirect evidence of a placebo
effect in migraine attack treatment, comes from the high
amplitude of the improvement observed in the placebo
arms (28% of the patients). This ﬁgure is lower (6%) when
using the harder criterium of pain free at 2 h. But these data
disregard the effect of the natural course. For prophylactic
treatment with oral medication, the trials performed in the
last decades report an improvement in 21% of the patients
in the placebo arms. However, in these studies the duration
of administration was limited, the control of attacks
uncertain as well as the evolution of the co-morbid psycho-
pathology. Considering the reviews and meta-analysis of
complex prophylactic procedures, it must be concluded that
their effect is mostly linked to a placebo and non-speciﬁc
psychological effects. Acupuncture may have a slight
speciﬁc effect on tension type headache, but not on
migraine. Manual therapy studies do not exhibit difference
between manipulation, mobilization, and controls; touch
has no proven speciﬁc effect. A comprehensive efﬁcacy
review of biofeedback studies concludes to a small speciﬁc
effect on tension type headache but not on migraine. A
review of behavioral treatment conclude to an interesting
mean improvement but did not demonstrated a speciﬁc
effect with the exception of a four arm study including
a pseudo meditation control group. Expectation-linked
placebo, conditioning, and non-speciﬁc psychological
effects vary according clinical situations and psychological
context; likely low in RCT, high after anempathic medical
contact, and at its maximum with a desired charismatic
healer. The announcements of doctors strongly inﬂuence
the beliefs of patients, and in consequence their pain and
anxiety sensibilities; this modulates the amplitude of the
placebo and the non-speciﬁc psychological effects and is
therefore a major determinant of the therapeutic success.
Furthermore,anyrepetitivecontact, eventhroughaplacebo,
may interfere positively with the psychopathological
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Introduction
In pre-scientiﬁc civilizations, suggestions of the healer and
the beliefs of the patients were the mainstays of headache
treatment: in the Ebers papyrus [1], which was written in
approximately 1200 BC, one treatment was to ﬁrmly bind a
clay crocodile holding a grain in its mouth to the patient’s
head with a strip of linen bearing the names of the gods.
Another was to use a bandage with honey and coriander. In
the dialogues of Plato (Charmides), approximately 400 BC,
Socrates states that he used a leaf and a charm to treat
headache.
The aim of this review is to determine from studies
currently available in the PubMed database (US National
Library of Medicine, National Daily Institutes of Health),
how placebo and psychological effects take their place
beside the biological speciﬁc action of treatments in the
headache management. To assess this issue, we present
successively a review of the basic studies on placebo
effect, the contribution of the randomized control trials
(RTC) in headache, and a sketch of a theory on headache
treatment healing in clinical practice, with a special regard
on the psychological interactions.
Some basic considerations concerning placebo
Interestingly, one had to wait until Hooper’s English
medical dictionary in 1811 to see in the medical literature,
the word ‘‘placebo’’. It was used to designate a medicine
given more to please than to treat (see [2]). The placebo is
therefore, basically, an inert product which has to be
compared to the active principle called verum; by exten-
sion, a complex therapeutic procedure has also to be
compared to a sham (placebo) procedure. The scientiﬁc
debate about placebo in therapeutic trials began in 1955 in
a seminal article by Beecher [3] entitled ‘‘The powerful
placebo’’. This ‘‘power’’ remains controversial due to the
concomitant confusion factors which have been compre-
hensively reviewed [4] (natural course of the disease,
additional treatment, observer bias, irrelevant response,
verum toxicity, patient bias, misquotation…)[ 5–7]. As we
shall see below these misleading factors have to be con-
trolled by an appropriated methodology. At the turn of the
last century, a bio-psychological approach with several
powerful studies shed light on the placebo phenomena [8].
Inﬂuence of what is offer to the patients
The color and number of pills inﬂuence the outcome
[9, 10]: placebo tablets given to students and told to have a
psychological effect act as stimulants when they are red
and depressants when blue, and two placebo pills have a
higher effect than one. The branding increases the placebo
effect [11]. Parenteral or subcutaneous administration is
more efﬁcient than oral administration [12, 13]. A pseudo-
acupuncture sham device had a greater effect than a pla-
cebo pill in chronic arm pain [14]. Finally, the more
complex the procedure including rituals, mysterious pow-
ers, high technology and surgery, the larger the effects that
are seen [13, 14].
The associated announcement is of paramount impor-
tance. A placebo cream presented as a powerful local
anesthetic only induces an effect where it is applied [15].
The amplitude of the analgesic effect of saline given as a
pain-killer after thoracic surgery depends on previously
announced analgesic power [16]. In healthy young adults,
an exercise program induces psychological well-being only
in the group where this psychological effect has been
announced and emphasized [17].
Practitioners’ attitude inﬂuences the placebo effect: in
irritable bowel syndrome treated by pseudo-acupuncture, a
warm empathic interaction enhances the placebo effect, but
only in patients with an high extraversion proﬁle [18].
Patients’ expectations and personality
The desire to be relieved, the expectations from the pro-
cedure, the memory of previous effects [19, 20], and the
overt and covert meanings of the procedure [8] inﬂuence
the placebo effect according to an expectation response
theory in which expectations are the major determinant of
what will occur in a given situation [21].
However, a relationship between the placebo reactivity
and a given psychological or a socio-cultural state was not
evidenced in a large study on patients with a persistent
distal upper arm pain; the dimensions tested were: anxiety,
depression, belief in alternative medicine, sex, color
(white/non-white), educational level, and age [22].
Genuine placebo effect and confusion factors
The placebo effect linked to expectation is, therefore, a
consequence of the idea of having received the verum. This
genuine placebo effects have to be differentiated from the
contingent events and from the natural course of the disease
during the same period. In RCT, patients are often included
when their symptoms worsen above a certain threshold.
This threshold can be misleadingly reached when a ﬂuctu-
ating symptom is at its maximum or when it is erroneously
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mean of the symptoms may have no biological signiﬁcation
(see review in [23]). Accordingly, a placebo effect can only
be measured when comparing patients treated with placebo
to non-treated patients during the same time period [7].
Even in this case, a bias can occur in the non-treated group
due to the negative impact of lack of treatment.
Neurobiology of the placebo effects associated
with expectations
The ﬁrst step was the discovery of a link between expec-
tation, placebo improvement and opioidergic mediation.
Indeed, after molar extraction, naloxone, a l-opioid
receptor antagonist, reduced the beneﬁcial effect of saline
that was presented as an analgesic [24].
Pioneering work in PET and in fMRI showed that the
expectation linked placebo analgesia was associated with
increased activity in the rostral anterior cingulum [25, 26].
Using PET measurements of the ﬁxation potential of 11C-
carfentanil, a l-opioid receptor ligand, several authors [27,
28] showed the implication of an opioidergic network
involving pre-frontal and anterior cingular cortex, accum-
bens nuclei and peri-acqueducal gray in expectation linked
placebo effect. The meso-limbic and orbito-frontal dopa-
minergic systems has also been demonstrated to be impli-
cated by simultaneously measuring the ﬁxation potential of
11C-raclopride, a D2/D3 agonist. The placebo-induced
expectation is associated with a bilateral increase in
dopaminergic activity in the ventral putamen and nucleus
accumbens, which seem to play a trigger role in l-opio-
idergic activation. Furthermore, it has been shown that an
increase in pain sensation (i.e., a nocebo effect) is associ-
ated with opioid and dopaminergic deactivation [29].
Finally, l-opioidergic and D2/D3 dopaminergic systems
are activated to different degrees, depending on the
patient’s positive (placebo) or negative (nocebo) expecta-
tion [30]. The analgesic placebo-induced expectation net-
work is a part of a wider emotion control system [31].
Conditioning
A conditioning effect, not linked to expectations has been
demonstrated. A study by Pavlov showed that, after cou-
pling a tone (neutral stimulus) and apomorphine (uncon-
ditioned stimulus), the drug-induced symptoms still
continue only after sound alone. There are several animal
studies demonstrating that saline can induce an effect when
replacing a drug given before repeatedly (see review in
[32]). Such a conditioning has been demonstrated in
humans, using the tourniquet paradigm (measuring daily
the duration of hand contraction under ischemia); indeed
ketorolac administered repeatedly reduced the pain
sensation; then its substitution by a placebo, presented as
an antibiotic was associated with the persistence of an
analgesic effect; this effect persisted when the placebo was
associated with naloxone [33]: this interesting experience
demonstrates that in human, a conditioning may induce an
analgesia which is not linked to an expectation, nor to an
opioidergic mechanism.
When a treatment is given repeatedly, conditioning and
expectation are intermingled, and the effect is reinforced
with the length of the symptom-free period [34]. In an
interesting study, conditioning was revealed to have a more
powerful analgesic effect than expectation [32].
Lessons given by RCT
We assume that the outcome of headache management is
the result of additive actions of (1) a speciﬁc effect on
headache mechanisms, (2) a placebo effect linked to the
idea of having received the verum, and (3) a non-speciﬁc
psychological covert intervention (empathy, kind listening,
etc…) which can be at its maximum in some complex
therapeutic procedures as acupuncture, touch and manual
therapy, biofeedback.
Therefore, to demonstrate a genuine placebo effect for
an oral treatment, one should ideally use, at least, a three
arm trial design (verum, placebo, and no treatment) [6].
Differences between the verum and placebo reﬂect the
speciﬁc effect. Differences between the placebo and no
treatment measure the placebo effect. To analyze the
complex procedure effect one should, also, control the non-
speciﬁc psychological covert intervention by the mean of a
pertinent ‘‘psychological’’ control group. Bias may come
from a non-convincing sham procedure, or from the neg-
ative effect of being included in a ‘‘psychological’’, or in a
non-treated control group.
At this point, it appears interesting to clarify the rela-
tionships between placebo, non speciﬁc psychological
intervention and psychotherapy [35]. The three act through
psychological processes. Placebo effect is simply mostly
based on an expectation after the announcement of given
therapy and after conditioning, the non-speciﬁc psycho-
logical intervention is limited to empathy, kind listening
without psychological base, and psychotherapy acts mostly
through speciﬁc intentionally delivered psychological
interactions.
Acute treatment for headache attacks
No three arm trials have studied acute treatment [36]. In
migraine, meta-analysis [37–42] of placebo arms show that
in adult patients, at 2 h, a two point improvement (using
a 0–3 scale) is seen in about 28–29% of patients and a
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of 29% for pain-free), however, with a high heterogeneity
[40]. These ﬁgures demonstrate the speciﬁc effect of the
verum included in the meta-analysis, and their amplitude
suggests that a genuine placebo effect does exist, mostly
when a permissive outcome is chosen. A high placebo
efﬁcacy is reported in children: meta-analysis of 13 studies
found that at 2 h after administration, improvement was
seen in 33% (23–43%) of children, and a pain-free state in
14% (9–18%) [43].
A meta-analysis of 37 studies about the treatment of
tension type headache attacks shows that NSAIDs and
acetaminophen have a signiﬁcant speciﬁc effect [44], but
not data are available to analyze a putative placebo effect.
Prophylactic treatment and placebo effect
From a comprehensive meta-analysis of three arm trials
[36], only ﬁve studied headache exclusively [45–49];
unfortunately, none of these studies considered the actual
IHS classiﬁcation. Only one three arm trial concerned oral
medication, given 2 weeks, and did not evidence for a
difference in headache score between the placebo an
no-treatment [47].
In a comprehensive meta-analysis of oral prophylactic
treatments RCT of migraine (32 studies) [50], the per-
centage of patients presenting a 50% reduction in the
number of days with headache reported in the placebo arms
is 21% (13–28%). There was a signiﬁcant heterogeneity.
The corresponding data for the verum was 41% (33–49%).
The improvement under placebo was greater in parallel
compared to cross-over studies and in European compared
to North American trials. These studies were performed
between 1998 and 2004, usually lasted 12 weeks and did
not mention the level of control of the acute attacks. A
recent follow-up during 16 months of migraine patients
with an optimized attack treatment [51] showed an
improvement with time without differences between pla-
cebo alone, beta blockers alone, or placebo associated with
behavioral management, suggesting that the administration
of any treatment, even a placebo, is sufﬁcient to achieve an
apparent therapeutic success [51].
In conclusion, a speciﬁc effect of the prophylactic oral
treatments included in the meta-analysis seems to be
demonstrated [52] only for a relatively short time use. A
prophylactic effect of placebo is also suggested [50] for a
short time period by the amplitude of the improvement
observed in the placebo arm. Finally, one study suggests a
placebo prophylactic efﬁcacy for a long period [51].
Meta-analysis of studies of tension type headache pro-
phylaxis with oral treatment provide conﬂicting results: a
lack of superiority of antidepressant medication or myor-
elaxants over placebo is reported in one study [53], and a
beneﬁcial effect of tricyclic antidepressants in two others
[54, 55]. No data are presented to evaluate a putative pla-
cebo effect. Interestingly, the follow-up of four groups of
patients with chronic tension-type headache [54] treated
with anti-depressant medication or placebo with or without
stress-management therapy, showed that the placebo had a
non-different effect compared to the anti-depressant med-
ication or stress-management therapy given alone on
headache activity in the sub-group with initial low CTTH
severity and on disability in the sub-group without initial
mood and anxiety disorders [56]. This part of the data
raises the issue of the placebo efﬁcacy in CTTH of low
severity.
The effects of acupuncture in migraine prevention have
been evaluated by one meta-analysis [57]: true acupuncture
was not superior to sham acupuncture, but is superior to no
treatment up to 4 months after treatment (effect size 0.44
SD). In tension type headache, two meta-analysis [58, 59]
revealed a small advantage of true acupuncture over sham
acupuncture, in fact linked to one heavy positive study
[60]. One have to conclude to a lack of speciﬁc effect of
acupuncture on migraine and to a questionable speciﬁc
effect of this procedure on tension-type headache. Acu-
puncture seems to act mostly through a high placebo and
non-speciﬁc psychological effect.
A cervical pain trial meta-analysis studying manual
therapy [61] found that manipulation (high velocity low
amplitude) and mobilization produce similar effects on
pain and are not better at short- and intermediate-term than
controls for pain relief. Consequently, no speciﬁc and no
signiﬁcant placebo effects have been demonstrated. How-
ever, interpersonal touch has a major impact in our
everyday social interactions [62], and has been used as a
therapy since the dawn of humanity. Touch therapy is more
or less codiﬁed (healing touch, therapeutic touch, Reiki)
and is consistently associated with a special surrounding
that can be considered as having a ‘‘non-speciﬁc’’ psy-
chological inﬂuence. A meta-analysis of studies conducted
on touch therapy for pain [63] includes only one incon-
clusive study [64] on tension type headache. Therefore, no
conclusion about the speciﬁc effect of touch on headache
can be drawn.
An interesting three arm study [49] on chronic headache
sufferers treated by soft manual therapy with relaxation
(Trager’s technique), controlled ‘‘attentional’’ visits, or no
treatment shows a higher improvement of quality of life in
the two treated groups compared to the no-treatment group.
Consequently, no speciﬁc effect can be concluded from this
open study. The improvement in the two groups may be
due to the psychological non-speciﬁc effect.
Interestingly, the beneﬁcial effect of sham acupuncture
on headache has been proposed as a model of ritual healing
by touch [65], which provides one way to explain the
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no-treatment.
A comprehensive efﬁcacy review of biofeedback (BFB)
[66] concluded that true BFB is not signiﬁcantly superior to
sham BFB in migraine (effect size 0.25, conﬁdence interval
95% 0.49–0.00) but did show a small advantage of true
BIB over sham in tension-type headaches (effect size 0.50,
conﬁdence interval 95% 0.26–0.75). In both conditions,
BFB is superior to the waiting list. Thus, BFB seems to
have a speciﬁc beneﬁcial effect on tension type headache.
The superiority of pseudo BFB on the waiting list may be
due to the additive effect of the non-speciﬁc psychological
effect and the placebo effect of BFB.
In children, an interesting three arm study [48] (warm-
ing BFB associated with cognitive stress management
therapy, pseudo BFB associated with an attention therapy,
waiting-list) did not ﬁnd evidence for signiﬁcant inter-
treatment difference and cannot conclude to a speciﬁc
effect.
A review of the studies of behavioral treatment of
headache [67] reports a 35–55% improvement but also
emphasizes many methodological imperfections, including
selection bias, credibility of the control procedure, and lack
of reproducibility of the results. In addition, most of these
studies were performed more than 30 years ago, and a
control waiting list group was not reported. Among these
studies, an interesting one [46] compares four treatments
for tension headache (relaxation, relaxation ? cognitive
therapy, pseudo-meditation, and waiting list) and reports a
signiﬁcantly better improvement of a headache index for
the two groups treated with relaxation compared to the
pseudo-meditation group. Pseudo-meditation consisted of
an equal number of sessions in which subjects were
engaged in imaging daily activity without becoming
relaxed, and is therefore a control of the relaxation. This
study provides evidence for a speciﬁc effect of relaxation
on tension type headache prophylaxis.
As conclusions from this review on RCT
A speciﬁc effect of treatment has been demonstrated by
meta-analysis in several situation: (1) oral treatment of
migraine, and tension type headache attacks, (2) oral
treatment for migraine prevention during usually a
12-week administration, regardless the level of control of
the attack and the underlying anxio-depressive state. In
tension type headache, a questionable speciﬁc effect is also
reported for acupuncture and for BFB associated with
relaxation, and, by one study for relaxation.
A placebo effect is likely associated with every kind of
treatment. However the evidences are only indirect. (1) In
migraine attack, the amplitude of the improvement in the
placebo arms (about half of that observed in the verum
arms, if we disregard the improvement due to the natural
course) replaces a demonstration. However if we consider
the harder outcome of pain free at 2 h, this placebo effect is
only about a ﬁfth of that of verum. (2) In oral prophylaxis
of migraine, the meta-analysis of short-term RCT reports
also an improvement half of that of verum for placebo-
treated patients, which is also an indirect proof of a
short-term genuine placebo effect. Interestingly one study
suggest a long-term placebo effect in chronic tension type
headache in patients with a moderate disability or with a
low initial anxio-depressive level, and in migraine patient
with an optimal attack control.
Both placebo and non speciﬁc psychological effect are
likely at the origin of the improvement induced by many
procedures (migraine prophylaxis by acupuncture or bio-
feedback, headache in general for manual therapy, touch
and behavioral treatment) on the evidences that for these
techniques in these precise conditions, the patents improve
though no speciﬁc effect has ever been demonstrated. The
non- speciﬁc psychological effects of these complex pro-
cedures in headache treatments refer to the ‘‘common
factors’’ shared by the various modalities of psychothera-
pies (see review in [68]
Towards a theory of the treatment for headache
sufferers
Expectation-linked placebo, and non-speciﬁc psychologi-
cal effects, and conditioning, vary according clinical situ-
ations and psychological context of the patients.
Variability of expectation linked placebo
and conditioning effects (see also review [69])
The placebo effect linked to expectation is likely low in
RCT as this situation does not favor a full effect of sug-
gestion because of the formality of the inclusion,
announcement of the side-effects and the known eventu-
ality of receiving a non-active drug. Conversely, sugges-
tions in clinical daily practice may be of great importance:
a positive enthusiastic announcement of a beneﬁcial effect
will certainly have a better therapeutic effect than a
restrictive announcement putting forward side-effects. One
can formulate as a reasonable working hypothesis that the
efﬁcacy of some charismatic healers or shamans may be
associated to massive l-opioidergic/D2D3-dopaminergic
mobilization. Furthermore, in prophylactic repetitive
treatment, which is equivalent to a ritual, the effects of
suggestion and conditioning are intermingled, likely reen-
forced by a long delay of occurrence, and a good control of
the ﬁrst attack [56]. Consequently, the more a prophylactic
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working.
Inﬂuence of the psychological and psychopathological
context
Repeated headaches induce negative affects with negative
cognitive, affective (pain fear) and physiologic conse-
quences, according to an individual dimension of ‘‘pain
sensibility’’. In return, negative effects can induce attacks,
increase their intensity and the subsequent disability
according to an individual ‘‘anxiety sensitivity’’ [70, 71]
(Table 1; Fig. 1). Both ‘‘pain sensibility’’ and ‘‘anxiety
sensibility’’ depend on beliefs, as placebo/nocebo phe-
nomena depend on expectations. In daily clinical practice,
the announcements of doctors strongly inﬂuence the
expectations and beliefs of patients, which then inﬂuence
the amplitude of placebo effect and of the pain and anxiety
sensibilities, and are therefore a major determinant for a
therapeutic success. There is an increase in psycho-
pathological co-morbidity in chronic migraine and tension
type headache [72, 73]. Consequently, any repetitive
treatment, even a placebo, acting on this dimension may
modify the natural course of the disease [74]. According to
Frank [68], this beneﬁcial effect may be due to the
reduction of the ‘‘demoralization’’, likely presented by the
headache sufferers.
Conclusion
Headache is the last phase of activation of neuronal net-
works and can be powerfully controlled by analgesic and
psychological systems. Suggestion from the outside,
internal beliefs and expectations, and psycho-pathological
context are deeply inﬂuenced by any therapeutic proposi-
tion. Inter-individual variations of these factors are poten-
tially highly important. Consequently, when a patient trusts
in a procedure, one has to accept the fact that this proce-
dure is effective for him and produces corresponding bio-
logical consequences. Speciﬁc treatments act effectively on
the common ﬁnal mechanisms of migraine or tension
headache in combination with the other non-speciﬁc factor.
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